MAIA Biotechnology (MAIA) Net Cash Flow (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Net Cash Flow of $25.7 million for Q1 2026, up 1944.65% year-over-year from $1.3 million in Q1 2025, and up 1260.5% quarter-over-quarter from -$2.2 million in Q4 2025.
MAIA Biotechnology (MAIA) Net Cash Flow (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Net Cash Flow for 6 consecutive years, with $25.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 1944.65% year-over-year to $25.7 million; the TTM figure through Mar 2026 stood at $23.5 million (up 805.25% YoY), while the FY2025 annual figure was -$938051.0, down 137.94% from the prior year.
- Net Cash Flow advanced to $25.7 million in Q1 2026 per MAIA's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $25.7 million in Q1 2026 and bottomed at -$3.4 million in Q1 2023.
- Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of -$276550.0 in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 1115.2% — and 2026, when it surged 1944.65%.
- MAIA Biotechnology's Net Cash Flow stood at -$3.1 million in 2022, then jumped by 132.87% to $1.0 million in 2023, then slipped by 9.26% to $937288.0 in 2024, then tumbled by 336.65% to -$2.2 million in 2025, then jumped by 1260.5% to $25.7 million in 2026.
- Business Quant data shows MAIA's Net Cash Flow at $25.7 million in Q1 2026, -$2.2 million in Q4 2025, and $748253.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -6.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.82 Mn |
| Jun 30, 2026 | -6.82 Mn |
| Mar 31, 2026 | 25.74 Mn |
| Mar 31, 2026 | 25.74 Mn |
| Dec 31, 2025 | -2.22 Mn |
| Dec 31, 2025 | -2.22 Mn |
| Sep 30, 2025 | 748,253.00 |
| Sep 30, 2025 | 748,253.00 |
| Jun 30, 2025 | -727,147.00 |
| Jun 30, 2025 | -727,147.00 |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 937,288.00 |
| Dec 31, 2024 | 937,288.00 |
| Sep 30, 2024 | -2.90 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.13 Mn |